101 related articles for article (PubMed ID: 21707612)
1. Comparison of different bile acid-phospholipid conjugates in acute hepatitis.
Pathil A; Warth A; Chamulitrat W; Stremmel W
Eur J Clin Invest; 2012 Feb; 42(2):130-8. PubMed ID: 21707612
[TBL] [Abstract][Full Text] [Related]
2. The synthetic bile acid-phospholipid conjugate ursodeoxycholyl lysophosphatidylethanolamide suppresses TNFα-induced liver injury.
Pathil A; Warth A; Chamulitrat W; Stremmel W
J Hepatol; 2011 Apr; 54(4):674-84. PubMed ID: 21146893
[TBL] [Abstract][Full Text] [Related]
3. Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease.
Pathil A; Mueller J; Warth A; Chamulitrat W; Stremmel W
Hepatology; 2012 May; 55(5):1369-78. PubMed ID: 22183915
[TBL] [Abstract][Full Text] [Related]
4. Ursodeoxycholyl Lysophosphatidylethanolamide modifies aberrant lipid profiles in NAFLD.
Pathil A; Liebisch G; Okun JG; Chamulitrat W; Schmitz G; Stremmel W
Eur J Clin Invest; 2015 Sep; 45(9):925-31. PubMed ID: 26108973
[TBL] [Abstract][Full Text] [Related]
5. Anti-inflammatory properties of ursodeoxycholyl lysophosphatidylethanolamide in endotoxin-mediated inflammatory liver injury.
Ludwig JM; Zhang Y; Chamulitrat W; Stremmel W; Pathil A
PLoS One; 2018; 13(5):e0197836. PubMed ID: 29795632
[TBL] [Abstract][Full Text] [Related]
6. Bile salt-phospholipid conjugate ursodeoxycholyl lysophosphatidylethanolamide as a hepatoprotective agent.
Chamulitrat W; Burhenne J; Rehlen T; Pathil A; Stremmel W
Hepatology; 2009 Jul; 50(1):143-54. PubMed ID: 19496180
[TBL] [Abstract][Full Text] [Related]
7. Ursodeoxycholyl lysophosphatidylethanolamide protects against hepatic ischemia and reperfusion injury in mice.
Wang J; Deng X; Yi S; Pathil A; Zhang W; Setchell K; Stremmel W; Chamulitrat W
Shock; 2015 Apr; 43(4):379-86. PubMed ID: 25526375
[TBL] [Abstract][Full Text] [Related]
8. Ursodeoxycholyl lysophosphatidylethanolamide attenuates hepatofibrogenesis by impairment of TGF-β1/Smad2/3 signalling.
Pathil A; Mueller J; Ludwig JM; Wang J; Warth A; Chamulitrat W; Stremmel W
Br J Pharmacol; 2014 Nov; 171(22):5113-26. PubMed ID: 25041068
[TBL] [Abstract][Full Text] [Related]
9. Ursodeoxycholyl Lysophosphatidylethanolamide Protects Against CD95/FAS-Induced Fulminant Hepatitis.
Utaipan T; Otto AC; Gan-Schreier H; Chunglok W; Pathil A; Stremmel W; Chamulitrat W
Shock; 2017 Aug; 48(2):251-259. PubMed ID: 28060213
[TBL] [Abstract][Full Text] [Related]
10. Ursodeoxycholyl lysophosphatidylethanolamide inhibits lipoapoptosis by shifting fatty acid pools toward monosaturated and polyunsaturated fatty acids in mouse hepatocytes.
Chamulitrat W; Liebisch G; Xu W; Gan-Schreier H; Pathil A; Schmitz G; Stremmel W
Mol Pharmacol; 2013 Nov; 84(5):696-709. PubMed ID: 23974795
[TBL] [Abstract][Full Text] [Related]
11. Ursodeoxycholyl lysophosphatidylethanolamide protects against hepatic ischemia/reperfusion injury via phospholipid metabolism-mediated mitochondrial quality control.
Gu J; Zhang T; Guo J; Chen K; Wang G; Li H; Wang J
FASEB J; 2020 May; 34(5):6198-6214. PubMed ID: 32162746
[TBL] [Abstract][Full Text] [Related]
12. Bivalent Ligand UDCA-LPE Inhibits Pro-Fibrogenic Integrin Signalling by Inducing Lipid Raft-Mediated Internalization.
Su J; Gan-Schreier H; Goeppert B; Chamulitrat W; Stremmel W; Pathil A
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30347788
[TBL] [Abstract][Full Text] [Related]
13. Ursodeoxycholyl lysophosphatidylethanolamide negatively regulates TLR-mediated lipopolysaccharide response in human THP-1-derived macrophages.
Horvatova A; Utaipan T; Otto AC; Zhang Y; Gan-Schreier H; Pavek P; Pathil A; Stremmel W; Chamulitrat W
Eur J Pharmacol; 2018 Apr; 825():63-74. PubMed ID: 29475064
[TBL] [Abstract][Full Text] [Related]
14. The Bile Acid-Phospholipid Conjugate Ursodeoxycholyl-Lysophosphatidylethanolamide (UDCA-LPE) Disintegrates the Lipid Backbone of Raft Plasma Membrane Domains by the Removal of the Membrane Phospholipase A2.
Stremmel W; Staffer S; Fricker G; Weiskirchen R
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31717968
[TBL] [Abstract][Full Text] [Related]
15. Long-term effect of treating pregnant rats with ursodeoxycholic acid on the congenital impairment of bile secretion induced in the pups by maternal cholestasis.
Macias RI; Serrano MA; Monte MJ; Jimenez S; Hernandez B; Marin JJ
J Pharmacol Exp Ther; 2005 Feb; 312(2):751-8. PubMed ID: 15452192
[TBL] [Abstract][Full Text] [Related]
16. Regulation of rat organic anion transporters in bile salt-induced cholestatic hepatitis: effect of ursodeoxycholate.
Rost D; Herrmann T; Sauer P; Schmidts HL; Stieger B; Meier PJ; Stremmel W; Stiehl A
Hepatology; 2003 Jul; 38(1):187-95. PubMed ID: 12830001
[TBL] [Abstract][Full Text] [Related]
17. Hepatoprotectant ursodeoxycholyl lysophosphatidylethanolamide increasing phosphatidylcholine levels as a potential therapy of acute liver injury.
Chamulitrat W; Zhang W; Xu W; Pathil A; Setchell K; Stremmel W
Front Physiol; 2012; 3():24. PubMed ID: 22363296
[TBL] [Abstract][Full Text] [Related]
18. Lipid raft-dependent death receptor 5 (DR5) expression and activation are critical for ursodeoxycholic acid-induced apoptosis in gastric cancer cells.
Lim SC; Duong HQ; Choi JE; Lee TB; Kang JH; Oh SH; Han SI
Carcinogenesis; 2011 May; 32(5):723-31. PubMed ID: 21362627
[TBL] [Abstract][Full Text] [Related]
19. Enteral donor pre-treatment with ursodeoxycholic acid protects the liver against ischaemia-reperfusion injury in rats.
Nowak G; Norén UG; Wernerson A; Marschall HU; Möller L; Ericzon BG
Transpl Int; 2005 May; 17(12):804-9. PubMed ID: 15815896
[TBL] [Abstract][Full Text] [Related]
20. Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells.
Arenas F; Hervias I; Uriz M; Joplin R; Prieto J; Medina JF
J Clin Invest; 2008 Feb; 118(2):695-709. PubMed ID: 18188457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
